GlassScriptPhysician profile
Frederick J Weigand
NPI 1003000522
$9,283.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,754 · 2020: $342 · 2021: $126 · 2022: $61.69.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,236.21 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $235.00 | 2019-2020 | |
| Novo Nordisk INC | $91.27 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $90.79 | 2019-2021 | |
| Lilly USA, LLC | $87.92 | 2019-2020 | |
| Amarin Pharma, INC. | $75.66 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.52 | 2019-2020 | |
| Abbvie INC. | $71.96 | 2021-2022 | |
| Glaxosmithkline, LLC. | $55.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $48.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.19 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $40.44 | 2019-2020 | |
| Organogenesis INC. | $38.93 | 2019 | |
| Amgen INC. | $32.81 | 2019 | |
| Leica Microsystems INC. | $21.67 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $21.30 | 2020 | |
| Pfizer INC. | $14.02 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Weigand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.